Why Rosacea-Ltd III Works - Rosacea-Ltd Advantages

This site is written for our Rosacea-Ltd III International customers.

To understand why Rosacea-Ltd III works, we should examine the "Pharmaceutical Mechanism of Action." The Rosacea-Ltd III disk allows for direct delivery of the ingredients to the skin for penetration and migration in the rosacea-affected area. The main ingredients of Rosacea-Ltd III are listed immediately below and following the ingredients you will find the "Pharmaceutical Mechanism of Action":

A. Zinc: Topically applied, zinc has been used for decades by various medical physicians for the treatment of inflammatory acne. Zinc has been used either as a primary ingredient or in conjunction with other anti-acne medications. Currently, zinc is found in several different active forms in hundreds of over-the-counter skin care products and anti-acne medications. Zinc has been shown to have a potent anti-septic effect (Drs. Provost and Farmer). More specifically, evidence suggests that zinc has anti-bacterial and anti-fungal actions, as well as mild anti-inflammatory actions (Drs. Rock, Wilkinson, and Ebling).
B. Sulfur: For over two decades, sulfur has been used for the treatment of rosacea, and clinical studies have demonstrated that it is extremely effective in the treatment of rosacea-related papules and pustules (Drs. Ellis and Strawiski). Many dermatologists tailor rosacea treatments to the individual by varying the concentration of sulfur in a given preparation (from 2 percent to 15 percent sulfur). Because rosacea is a chronic disease, treatment must usually be continued for a long period of time. For this reason, Drs. Blom and Hornmark were interested in a non-toxic, topically administered treatment that would be as effective as orally administered drugs such as antibiotics. To date, these physicians use topical sulfur as their primary anti-rosacea treatment (Drs. Blom and Hornmark). In a double-blind clinical study of 40 rosacea patients, these physicians found that rosacea-related papules and pustules responded much better to topical 10 percent sulfur than to oral antibiotics. More specifically, they found that with four weeks of topical sulfur treatment, the average number of papules and pustules dropped significantly (from 213 pimples before treatment to 17 pimples after treatment), and that this clearing was much better than that attained by treatment with oral tetracycline. In a separate series of clinical studies, similar results were found by Dr. Strauss and colleagues (Dr. Strauss).
C. Sodium Chloride, Copper Oxide, Magnesium Stearate and Polyethelene Glycol: These ingredients have long been well known for their anti-bacterial, anti-inflammatory actions, by which they reduce redness better than antibiotics, and their vascular constrictor action, which reduces overall facial redness whereas no other products constricts the dilated skin vessels as these ingredients do so well.

The Four Mechanisms of Action by which these primary ingredients work as listed above are as follows:

Rosacea-Ltd is a vascular constrictor, so it reduces the size of the capillaries that cause redness and blushing.
Rosacea-Ltd has a pH of approximately 7.0 (neutral). Many oral and topical treatments for rosacea are very acidic, which often makes for a continual problem for many rosacea sufferers and especially so in pregnancy and breast feeding. Rosacea-Ltd is 100% safe for use by pregnant and nursing mothers.
Rosacea-Ltd easily penetrates the skin and changes the pH of the skin. The penetration by the ingredients easily kills bacteria, virus and fungal cells by osmosis.
Rosacea-Ltd is anti-inflammatory, thereby reducing redness (much better than antibiotics which bacteria, virus & fungal cells become immune to after 2-5 months).

You do not have to live with inflamed rosacea which is often accompanied by acne pimples and sometimes seborrheic dermatitis. The following findings have been made:

Treatment with Rosacea-Ltd resulted in a visible decrease in rosacea-related facial redness. Most rosacea sufferers were able to see significant results in less than two weeks after the initial application.
Treatment with Rosacea-Ltd resulted in a reduction of the size of the capillaries (spidery vessels or spider veins) that cause redness and blushing within four to six weeks.
Treatment with Rosacea-Ltd resulted in a rapid clearing of rosacea papules and pustules within five to ten days, while assisting in the prevention of future acne pimples and rosacea-related papules.

Leave the face wet after washing and apply Rosacea-Ltd III. By simply gliding the Rosacea-Ltd III over the affected areas, the ingredients are dissolved onto the affected areas leaving an invisible application that is not noticeable on the skin. Rosacea-Ltd III is not a "cover up cosmetic" as it is invisible on the skin but using Rosacea-Ltd III according to your customized directions will result in a visible difference in the appearance and condition of your skin. Rosacea-Ltd III has more than 99% undiluted natural ingredients with a pH of 7.0 (the pH balance of normal skin). Furthermore, Rosacea-Ltd III is free of any potentially irritating preservatives, such as methylparaben, propylparaben, and Quaternium-15, and contains no irritating fragrances.

References:

1: Mazzatenta C, Giorgino G, Rubegni P, de Aloe G, Fimiani M.
Solid persistent facial oedema (Morbihan's disease) following rosacea, successfully treated with isotretinoin and ketotifen.
Br J Dermatol. 1997 Dec;137(6):1020-1.

2: Sharma VK, Lynn A, Kaminski M, Vasudeva R, Howden CW.
A study of the prevalence of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea.
Am J Gastroenterol. 1998 Feb;93(2):220-2.

3: Torresani C, Pavesi A, Manara GC.
Clarithromycin versus doxycycline in the treatment of rosacea.
Int J Dermatol. 1997 Dec;36(12):942-6.

4: Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA.
A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea.
Cutis. 1998 Jan;61(1):44-7.

5: Jansen T, Plewig G.
Fulminating rosacea conglobata (rosacea fulminans) and ulcerative colitis.
Br J Dermatol. 1997 Nov;137(5):830-1.

6: Juncker C, Honig M, Hormann K.
[Gigantic tumor of the nose. Rhinophyma]
HNO. 1997 Aug;45(8):636-7. German.

7: Sedlmaier B, Fuhrer A, Jovanovic S.
[New treatment possibilities for skin changes with the CO2 laser in head and neck surgery]
HNO. 1997 Aug;45(8):625-9. German.

8: Maseruka H, Bonshek RE, Tullo AB.
Tenascin-C expression in normal, inflamed, and scarred human corneas.
Br J Ophthalmol. 1997 Aug;81(8):677-82.

9: Ozer-Arasli A, Schwenn O, Dick B, Pfeiffer N.
[Endophthalmitis after cataract surgery: long-term follow-up]
Klin Monatsbl Augenheilkd. 1997 Sep;211(3):178-82. German.

10: Holland EJ, Schwartz GS.
Iatrogenic limbal stem cell deficiency.
Trans Am Ophthalmol Soc. 1997;95:95-107; discussion 107-10.

MORE ABOUT ROSACEA-LTD III

We continually update this site to keep you informed of the latest scientific findings about rosacea.

This page was last updated on May 9, 2008 .